Getinge Delivers Strong Q2 2026: Growth, Profitability Soar Amid Innovation Drive
July 19, 2026, 9:36 am
Getinge announced robust Q2 2026 results. Organic sales grew 4.6%, with EBITA margin hitting 17.6%. Strong cash flow reached SEK 1,001 million. Strategic product launches and an acquisition bolstered offerings. Geopolitical uncertainty persists, but Getinge maintains its 2026 organic sales growth forecast of 3-5%. The medical technology giant shows resilience and a clear path for future expansion. New innovations target enhanced patient care and optimized clinical workflows across global markets.
Getinge, a global leader in medical technology, posted impressive financial results for the second quarter of 2026. The period saw significant organic growth, high profitability, and robust cash flow. These figures highlight a strong operational performance across key business segments. The company demonstrated resilience amidst ongoing global economic complexities.
Organic sales increased by 4.6% in the April-June period. This growth signals solid market demand for Getinge’s diverse portfolio of healthcare solutions. Order intake also surged, rising organically by 6.2%. These metrics underscore the company's expanding market penetration and customer confidence.
Profitability metrics showed substantial improvement. The adjusted EBITA margin reached an impressive 17.6%. This figure received a positive boost from a tariff refund totaling approximately SEK 336 million. Excluding the net impact of tariffs and currency fluctuations, the adjusted EBITA margin stood at a healthy 15.2%. This underlying performance reflects effective cost management and a favorable product mix. Gross profit margins also expanded, reaching 55.4% for the quarter. Earnings per share grew significantly, hitting SEK 3.59.
Cash flow generation was particularly strong. Free cash flow amounted to SEK 1,001 million for the second quarter. This robust cash position provides Getinge with ample financial flexibility. It supports continued investment in research and development, strategic acquisitions, and operational enhancements.
A deeper look into business segments reveals varied performance. Acute Care Therapies experienced increased sales across most product categories. Consumables for life-supporting ECLS therapy maintained a positive trend. This segment continues to be a crucial growth driver for Getinge, addressing critical patient needs.
Surgical Workflows displayed consistent positive momentum. This area focuses on optimizing operating room efficiency and safety. Getinge’s solutions in surgical workflows are essential for modern healthcare facilities. They enhance clinical outcomes and streamline complex procedures.
The Life Science segment presented a mixed picture. The high-margin Sterile Transfer category reported double-digit growth in both order intake and sales. This success highlights demand for critical sterile processing solutions. However, the pharma sector’s investment appetite remains cautious. Geopolitical uncertainty plays a significant role here. This caution primarily impacts the project-based and capital-intensive product category of WIS. Such large-scale projects are often sensitive to broader economic and political stability.
Innovation remains a core pillar of Getinge’s strategy. The company launched several new products during the quarter. These innovations enhance its offering and provide greater value to customers. A new product generation within endoscopic vessel harvesting (EVH) debuted. This development promises improved minimally invasive surgical techniques.
Another key launch involved a system for automated endoscope reprocessing. This system increases capacity and enhances safety in a critical area of infection prevention. Getinge also expanded its fluorescence imaging portfolio. A new product for small-incision surgery emerged. These advancements underscore Getinge’s commitment to cutting-edge medical technology.
Regulatory milestones were also achieved. The 510(k)-application for the Cardiosave intra-aortic balloon pump was submitted to the FDA in June. This submission represents a critical step towards bringing advanced cardiovascular support to more patients. Regulatory approvals are vital for market access and global expansion.
Strategic acquisitions further strengthened Getinge’s market position. The company acquired Pennamed, a UK-based distributor of endoscopic consumables. This move directly bolsters Getinge’s infection prevention offering in endoscopy. Such targeted acquisitions expand reach and capabilities.
Investment in future capabilities continued. A new innovation center opened in Hamburg. This center aims to accelerate the development of intelligent, digital perioperative workflows. Digitalization is transforming healthcare. Getinge is positioning itself at the forefront of this evolution. These digital solutions promise greater efficiency and improved patient care pathways.
Looking ahead, Getinge maintains its forecast for 2026. The company anticipates organic sales growth of 3-5% for the full year. This outlook is grounded in regular customer dialogue. It reflects confidence in Getinge’s product portfolio and market position. Geopolitical uncertainty persists, but Getinge remains focused on its strategic priorities.
Overall, the first half of 2026 also shows solid performance. Organic sales increased by 2.7%. Order intake rose by 5.0% organically. Adjusted EBITA margin reached 14.5%. Free cash flow for the first six months stood at SEK 1,843 million. These figures demonstrate consistent positive momentum throughout the year.
Getinge’s mission centers on providing access to the best possible care. Its products and solutions support hospitals and life science institutions globally. The company aims to improve clinical results and optimize workflows. Its extensive offering covers intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science. Getinge employs approximately 12,000 people worldwide. Its products are sold in over 135 countries. This global footprint and broad portfolio solidify its standing as a vital partner in healthcare. The Q2 2026 results affirm its strategic direction and operational effectiveness.
Getinge, a global leader in medical technology, posted impressive financial results for the second quarter of 2026. The period saw significant organic growth, high profitability, and robust cash flow. These figures highlight a strong operational performance across key business segments. The company demonstrated resilience amidst ongoing global economic complexities.
Organic sales increased by 4.6% in the April-June period. This growth signals solid market demand for Getinge’s diverse portfolio of healthcare solutions. Order intake also surged, rising organically by 6.2%. These metrics underscore the company's expanding market penetration and customer confidence.
Profitability metrics showed substantial improvement. The adjusted EBITA margin reached an impressive 17.6%. This figure received a positive boost from a tariff refund totaling approximately SEK 336 million. Excluding the net impact of tariffs and currency fluctuations, the adjusted EBITA margin stood at a healthy 15.2%. This underlying performance reflects effective cost management and a favorable product mix. Gross profit margins also expanded, reaching 55.4% for the quarter. Earnings per share grew significantly, hitting SEK 3.59.
Cash flow generation was particularly strong. Free cash flow amounted to SEK 1,001 million for the second quarter. This robust cash position provides Getinge with ample financial flexibility. It supports continued investment in research and development, strategic acquisitions, and operational enhancements.
A deeper look into business segments reveals varied performance. Acute Care Therapies experienced increased sales across most product categories. Consumables for life-supporting ECLS therapy maintained a positive trend. This segment continues to be a crucial growth driver for Getinge, addressing critical patient needs.
Surgical Workflows displayed consistent positive momentum. This area focuses on optimizing operating room efficiency and safety. Getinge’s solutions in surgical workflows are essential for modern healthcare facilities. They enhance clinical outcomes and streamline complex procedures.
The Life Science segment presented a mixed picture. The high-margin Sterile Transfer category reported double-digit growth in both order intake and sales. This success highlights demand for critical sterile processing solutions. However, the pharma sector’s investment appetite remains cautious. Geopolitical uncertainty plays a significant role here. This caution primarily impacts the project-based and capital-intensive product category of WIS. Such large-scale projects are often sensitive to broader economic and political stability.
Innovation remains a core pillar of Getinge’s strategy. The company launched several new products during the quarter. These innovations enhance its offering and provide greater value to customers. A new product generation within endoscopic vessel harvesting (EVH) debuted. This development promises improved minimally invasive surgical techniques.
Another key launch involved a system for automated endoscope reprocessing. This system increases capacity and enhances safety in a critical area of infection prevention. Getinge also expanded its fluorescence imaging portfolio. A new product for small-incision surgery emerged. These advancements underscore Getinge’s commitment to cutting-edge medical technology.
Regulatory milestones were also achieved. The 510(k)-application for the Cardiosave intra-aortic balloon pump was submitted to the FDA in June. This submission represents a critical step towards bringing advanced cardiovascular support to more patients. Regulatory approvals are vital for market access and global expansion.
Strategic acquisitions further strengthened Getinge’s market position. The company acquired Pennamed, a UK-based distributor of endoscopic consumables. This move directly bolsters Getinge’s infection prevention offering in endoscopy. Such targeted acquisitions expand reach and capabilities.
Investment in future capabilities continued. A new innovation center opened in Hamburg. This center aims to accelerate the development of intelligent, digital perioperative workflows. Digitalization is transforming healthcare. Getinge is positioning itself at the forefront of this evolution. These digital solutions promise greater efficiency and improved patient care pathways.
Looking ahead, Getinge maintains its forecast for 2026. The company anticipates organic sales growth of 3-5% for the full year. This outlook is grounded in regular customer dialogue. It reflects confidence in Getinge’s product portfolio and market position. Geopolitical uncertainty persists, but Getinge remains focused on its strategic priorities.
Overall, the first half of 2026 also shows solid performance. Organic sales increased by 2.7%. Order intake rose by 5.0% organically. Adjusted EBITA margin reached 14.5%. Free cash flow for the first six months stood at SEK 1,843 million. These figures demonstrate consistent positive momentum throughout the year.
Getinge’s mission centers on providing access to the best possible care. Its products and solutions support hospitals and life science institutions globally. The company aims to improve clinical results and optimize workflows. Its extensive offering covers intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science. Getinge employs approximately 12,000 people worldwide. Its products are sold in over 135 countries. This global footprint and broad portfolio solidify its standing as a vital partner in healthcare. The Q2 2026 results affirm its strategic direction and operational effectiveness.